SYK:NYE-Stryker Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 388.52

Change

+2.91 (+0.75)%

Market Cap

USD 41.39B

Volume

0.83M

Analyst Target

USD 217.70
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Stryker Corp is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+1.04 (+0.79%)

USD 221.89B
MDT Medtronic PLC

+0.94 (+1.08%)

USD 116.46B
SEMHF Siemens Healthineers AG

N/A

USD 67.08B
STE STERIS plc

-0.60 (-0.27%)

USD 21.55B
ZBH Zimmer Biomet Holdings Inc

+0.29 (+0.28%)

USD 20.01B
GMED Globus Medical

+0.03 (+0.04%)

USD 11.43B
SNN Smith & Nephew SNATS Inc

+0.10 (+0.39%)

USD 11.17B
PEN Penumbra Inc

-0.64 (-0.21%)

USD 10.31B
BIO Bio-Rad Laboratories Inc

+1.90 (+0.67%)

USD 10.09B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.59B

ETFs Containing SYK

UMDV:SW iShares US Medical Device.. 10.25 % 0.00 %

N/A

N/A
CYBG:LSE VanEck Bionic Engineering.. 9.94 % 0.00 %

-0.16 (0%)

N/A
CIB0:XETRA 9.85 % 0.00 %

N/A

N/A
JGRW Trust For Professional Ma.. 6.28 % 0.00 %

-0.07 (0%)

USD 0.09B
MHCD:CA Middlefield Healthcare Di.. 4.49 % 0.00 %

+0.07 (+0%)

CAD 0.16B
XDG3:XETRA 4.11 % 0.00 %

N/A

N/A
FOHW:XETRA 2.52 % 0.00 %

N/A

N/A
FTCS:LSE First Trust Capital Stren.. 2.03 % 0.00 %

-0.04 (0%)

USD 8.53M
XMLH:F 1.82 % 0.00 %

N/A

N/A
DOCT:SW L&G Healthcare Breakthrou.. 1.82 % 0.00 %

-0.08 (0%)

USD 0.07B
CWS AdvisorShares Focused Equ.. 0.00 % 0.68 %

-0.13 (0%)

USD 0.18B
HAWX iShares Currency Hedged M.. 0.00 % 0.03 %

+0.07 (+0%)

USD 0.25B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

N/A

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
HTEC Robo Global® Healthcare .. 0.00 % 0.00 %

-0.37 (0%)

USD 0.05B
LIFE:CA Evolve Global Healthcare .. 0.00 % 0.69 %

+0.12 (+0%)

CAD 0.22B
GOAI:PA Amundi Stoxx Global Artif.. 0.00 % 0.00 %

-1.54 (0%)

USD 1.01B
GOAI:F 0.00 % 0.00 %

N/A

N/A
GOAI:XETRA 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA 0.00 % 0.00 %

N/A

N/A
TACE 0.00 % 0.00 %

N/A

N/A
DEMZ Democratic Large Cap Core.. 0.00 % 0.00 %

-0.16 (0%)

USD 0.04B
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.10 (+0%)

USD 0.06B
TDOC:CA TD Global Healthcare Lead.. 0.00 % 0.00 %

+0.02 (+0%)

CAD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.91% 65% D 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.91% 65% D 81% B-
Trailing 12 Months  
Capital Gain 11.79% 58% F 61% D-
Dividend Return 0.92% 29% F 13% F
Total Return 12.71% 58% F 56% F
Trailing 5 Years  
Capital Gain 73.21% 83% B 80% B-
Dividend Return 6.25% 63% D 18% F
Total Return 79.47% 83% B 79% B-
Average Annual (5 Year Horizon)  
Capital Gain 13.51% 65% D 72% C
Dividend Return 14.64% 65% D 70% C-
Total Return 1.12% 50% F 26% F
Risk Return Profile  
Volatility (Standard Deviation) 24.92% 74% C 44% F
Risk Adjusted Return 58.74% 90% A- 72% C
Market Capitalization 41.39B N/A N/A N/A N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.40 N/A N/A
Price/Book Ratio N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A
Return on Invested Capital N/A N/A N/A
Return on Assets N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.